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In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have
led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but
the search for treatments for renal fibrosis has been more disappointing. Here, we will
discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis
that acts upstream of major fibrosis signaling pathways. Its key role in renal fibrosis has
been validated in vitro and in several murine models of chronic kidney diseases (CKD).
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Background: Fibrosis and ESRD
Fibrosis is the final common pathway for chronic kidney diseases (CKD). Renal fibrosis occurs as an
overwhelming response to tissue injury. The attempt to repair damage begins with the recruitment
of inflammatory cells, but ends with an unchecked inflammatory response that activates matrix-
producing cells leading to tubular cell apoptosis, irreversible scarring, loss of renal function, and
ultimately end stage renal disease (ESRD) (Chuang et al., 2012). CKD and ESRD are major public
health problems with increasing prevalence worldwide and are associated with early mortality,
poor quality of life, and high healthcare costs. Unfortunately, at present, there are no effective
therapies to prevent or slow the progression of renal fibrosis, and the treatment options for patients
with ESRD are limited to dialysis and renal transplant. The blockade of the renin–angiotensin–
aldosterone system (RAAS) that nephrologists currently rely on for renal protection decreases the
risk of progression by only 20% (Drawz and Rosenberg, 2013). To develop effective molecular
targets for prevention and treatment of renal fibrosis, it is important to gain a better understanding
of the mechanisms involved.
Here, we will review major signaling pathways that contribute to aberrant wound healing and
fibrosis with a focus on homeodomain-interacting-protein kinase 2 (HIPK2) which acts upstream
of several pro-fibrosis pathways.
Signaling Pathways in Renal Fibrosis and Targeted Therapies
Novel drugs targeting the signaling pathways of renal fibrosis have generally given mixed results
and occasionally concerning side effects. The shortcomings of these experimental therapies are
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likely due to the fact that the pathogenesis of fibrosis is complex;
blockade of one pathway may still leave open many others for
promoting inflammation and fibrosis.
A central mediator in renal fibrosis is transforming growth
factor-β (TGF-β). TGF-β superfamily is highly conserved and
plays a major role in a variety of cellular responses including
cell proliferation, differentiation and apoptosis. TGF-β1, the
predominant isoform, stimulates extracellular matrix production
via Smad-dependent and Smad-independent mechanisms to
inhibit extracellular matrix degradation and promote expression
of pro-fibrosis genes in various cell types (Blobe et al., 2000;
Massagué and Wotton, 2000). TGF-β has also been shown to
exert pleiotropic effects in various cell types. In focal segmental
glomerulosclerosis, hyperplastic podocytes exhibit increased
TGF-β/Smad signaling which results in mesangial cell matrix
overproduction (Kim et al., 2003). In animal models of diabetic
nephropathy, increased TGF-β1 signaling leads to podocyte
apoptosis and glomerulosclerosis (Kim et al., 2003).
Recently, Eli Lilly sponsored a phase 2 trial for a humanized
neutralizing monoclonal antibody against TGF-β1 for the
treatment of advanced diabetic nephropathy, but the study had to
be prematurely terminated due to futility in efficacy. These data
were presented at the ASN 2014 and several issues of the study
design were raised by experts in the field during the meeting.
There are also concerns regarding anti-TGF-β therapies, since in
addition to its pro-fibrotic effects, it also exerts anti-inflammatory
effects; indiscriminate complete blockade of TGF-β functions can
promote inflammation.
Despite some disappointments in the field of renal fibrosis, the
FDA has recently approved two promising anti-fibrosis drugs,
pirfenidone and nintedanib, for the treatment of idiopathic
pulmonary fibrosis (IPF). These drugs are appealing because they
block chronic inflammation in addition to decreasing aberrant
wound healing. Pirfenidone has well-established anti-fibrotic and
anti-inflammatory properties in various in-vitro systems and
animal models of fibrosis (Schaefer et al., 2011). A number of
cell-based studies have shown that pirfenidone reduces fibroblast
proliferation, inhibits TGF-β stimulated collagen production
and reduces the production of fibrogenic mediators such as
TGF-β (Lee et al., 1998; Nakayama et al., 2008; Lin et al.,
2009). Pirfenidone has also been shown to reduce production
of inflammatory mediators such as TNF-α and IL-1β (Phillips
et al., 2005). These activities are consistent with the broader
anti-fibrotic and anti-inflammatory activities observed in animal
models of fibrosis. Pirfenidone is a drug developed by several
companies worldwide for the treatment of IPF. In 2008, it
was first approved in Japan for the treatment of IPF. While
pirfenidone has established safety and efficacy in treating human
pulmonary fibrosis and cirrhosis and is able to prevent kidney
fibrosis in rodents, these benefits have not yet been confirmed
in renal patients. In a study with 77 patients with kidney
disease, pirfenidone improved renal function but failed to
significantly reduce proteinuria (Ramachandrarao et al., 2009),
suggesting that pirfenidone improves renal fibrosis but does
not improve podocyte injury. Nintedanib is a small molecule
tyrosine-kinase inhibitor targeting vascular endothelial growth
factor, fibroblast growth factor receptor and platelet derived
growth factor receptor as an anti-angiogenesis and anti-cancer
agent (Roth et al., 2015). The role of Nintedanib has never been
determined in kidney disease.
Tranilast is another agent that is an anti-allergic drug and
has been used for the treatment of allergic disorders such as
asthma, allergic rhinitis and atopic dermatitis. However, in-vitro
studies show that it reduces collagen synthesis in fibroblasts,
and inhibits the production of interleukin-6 in endothelial cells
(Spiecker et al., 2002). Tranilast has been shown to improve renal
function in the subtotal nephrectomy CKDmodel in rodents and
to reduce albuminuria and slow progression of kidney disease
in a small cohort of renal patients (Soma et al., 2002; Spiecker
et al., 2002). However, when tranilast was used in patients with
cardiovascular disease to prevent major cardiovascular events
and restenosis after percutaneous coronary intervention, there
was a rise in creatinine afterwards suggesting that tranilast has
some nephrotoxicity (Holmes et al., 2002).
Bone-morphogenetic protein-7 (BMP-7) is part of the TGF-
β family and actually opposes the pro-fibrogenic effects of
TGF-β1 by blocking transcriptional upregulation of plasminogen
activator inhibitor-1 and antagonizing TGF-β-induced epithelial-
mesenchymal transition (Zeisberg et al., 2003). BMP-7 expression
is reduced in both animal models of diabetic nephropathy (DN)
and in DN patients, and is also downregulated in the rodent
model of ischemic acute tubular necrosis (Vukicevic et al.,
1998; Simon et al., 1999; De Petris et al., 2007). Consistent
with its TGF-β antagonizing role, exogenous recombinant BMP-
7 administration in vivo led to significant reduction of renal
fibrosis in pre-clinical models of diabetic nephropathy and CKD
(Wang, 2006). There are currently several phase 2 clinical trials
of agonists of BMP-7 signaling underway.
Connective tissue growth factor (CTGF) modulates TGF-
β and BMP-7 activities. CTGF is not expressed in normal
kidney but is upregulated in human kidney disease where it
enhances TGFβ-1 signaling resulting in myofibroblast activation,
fibronectin accumulation and tissue fibrosis (Yokoi et al., 2001;
Guha et al., 2007; Wang et al., 2011). In mouse models of
kidney disease, the reduction of CTGF prevents renal fibrosis.
In a small clinical trial, human anti-CTGF monoclonal antibody
significantly reduced albuminuria in patients with diabetic
nephropathy without significant adverse events (Adler et al.,
2010). FibroGen, Inc. started a phase 2 clinical trial designed
to evaluate the efficacy and safety of FG-3019, a fully human
monoclonal antibody against CTGF in patients with type 2
diabetes and advanced kidney disease in 2009. Unfortunately, this
clinical trial was terminated because of some regulation issues.
Despite some promising findings in animal studies and
small clinical trials, currently, anti-fibrosis drugs have yet to
be effectively translated into clinical practice in the field of
nephrology. The current strongest tool for renal protection
remains to be RAAS blockade which decreases the pro-fibrotic
effects of angiotensin II, thereby decreasing TGF-β and TGF-β
receptor levels in the kidney and decreasing expression of CTGF.
However, RAAS blockade is insufficient against renal fibrosis as it
only partially decreases the risk of progression, which highlights
the urgency for the development of more effective treatments for
renal fibrosis.
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HIPK2 in Renal Fibrosis
In order to determine which signaling networks are critical in
renal fibrosis Jin et al. developed a combined systems biology
and experimental approach to identify major signaling pathways
involved in gene expression changes in renal fibrosis (Jin et al.,
2012; Chen et al., 2013). TG-26 mice were used because they
are the murine model of HIV-associated nephropathy and
are a model of CKD. Their pathology is characterized by
diffuse segmental and global glomerulosclerosis with podocyte
foot process effacement, as well as significant tubulointerstitial
injury accompanied by heavy proteinuria, elevated blood urea
nitrogen, edema and hypoalbuminemia (Rosenstiel et al., 2009).
Jin et al. found differentially regulated transcription factors in
the kidneys of Tg-26 mice compared to wild-type control mice
and then identified upstream protein kinases that are likely to
phosphorylate those transcription factors. HIPK2 was identified
as one of the protein kinases with the highest ranks using
this approach. Subsequent experiments using gene ablation of
HIPK2 showed that it is a master regulator of kidney fibrosis in
experimental models of CKD.
HIPK2 Structure and Function
HIPK2 is part of the family of conserved serine/threonine
homeodomain-interacting kinases that localizes to nuclear
bodies. Structurally, its N-terminal domain consists of
a sumoylation site at lysine 25 and a 330 amino acid
serine/threonine kinase domain with a key catalytic site at
lysine residue, K221 (Figure 1) (Gresko et al., 2005; Hofmann
et al., 2005); the homeobox-interacting domain (HID), a protein–
protein interaction region, is followed by the speckle-retention
signal (SRS) which contains two PEST motifs and is required
for the subcellular localization of HIPK2 to nuclear bodies (Kim
et al., 1998); and its C-terminus contains the auto-inhibitory
domain (AID) with a ubiquitination site (K1182), which,
when cleaved by caspases leads to full activation of HIPK2.
HIPK2’s pleotropic functions include serving as co-regulator
of transcription factors, modulator of growth, development,
morphogenesis and cell death, tumor suppressor, and regulator
of response to DNA damage (Hofmann et al., 2001; D’Orazi et al.,
2002; Link et al., 2007; Bitomsky and Hofmann, 2009; Calzado
et al., 2014). A defective HIPK2-activated P53 system has been
implicated in the pathogenesis of idiopathic pulmonary fibrosis
(Ricci et al., 2013).
In renal tubular epithelial cells (RTEC), HIPK2 induced
expression of pro-fibrosis markers and apoptosis in HIV-
infected RTEC, likely due to its role in activating p53, TGF-β,
and Wnt/Notch pathways, which are each known to increase
expression of pro-fibrosis markers (Puca et al., 2010). Conversely,
suppression of HIPK2 activity via kinase dead (KD)-HIPK2
expression prevented TGF-β-induced expression of fibrosis
markers and attenuated HIV-induced apoptosis. In addition,
overexpression of WT-HIPK2 in HIV-infected RTECs enhanced
the expression of NF-κB targeted genes, while overexpression
of KD-HIPK2 suppressed NF-κB activation and inhibited the
expression of its downstream target genes. These data suggest
that HIPK2 mediates not only the fibrosis pathway but also
the inflammatory pathway. These results were further validated
in vivo using three different murine models of CKD (unilateral
ureteral obstruction or UUO, folic acid nephropathy and
HIVAN) by genetic ablation of HIPK2. In all three separate
models of CKD, loss of HIPK2 resulted in attenuation of renal
fibrosis, consistent with the role of HIPK2 as a regulator of gene
expressions involved in tubular injury and fibrosis.
HIPK2 Regulation is at Post-Translational
Level
HIPK2 is upregulated in fibrosis in murine kidney disease and
in human HIVAN, focal segmental glomerulosclerosis, diabetic
nephropathy and IgA nephropathy. However, this upregulation
appeared to be mediated through a post-translational regulation,
as the mRNA levels did not differ in Tg26 kidneys, while
there was a significant increase in protein detected by
immunohistochemistry. Indeed, the HIPK2 level was found to
be regulated through seven in absentia homolog-1 (SIAH-1)
mediated proteasomal degradation. However, oxidative stress,
such as from HIV infection, decreased SIAH-1 mRNA and
protein expression in vitro, resulting in an accumulation of
HIPK2. This inverse relationship between SIAH-1 and HIPK2
expression was confirmed in vivo in Tg26 mice, which had
decreased SIAH-1 expression in the renal cortex. While these
findings are intriguing, further reduction of HIPK2 staining in
late HIVAN glomeruli did not correlate with SIAH-1 expression
suggesting that there are other mechanisms besides SIAH-1 that
FIGURE 1 | Schema of HIPK2 Structure. HID, Homeoprotein-interacting domain; SRS, Speckle-retention signal; AID, auto-inhibitory domain; PEST, peptide
sequence rich in proline (P), glutamic acid (E), serine (S) and threonine (T); SIM, SUMO-interacting motif; Ub, ubiquitylation.
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regulate HIPK2. In fact, studies suggest that HIPK2 expression
is also downregulated by miR-141 interaction with HIPK2′s
3′ untranslated region which leads to upregulated e-cadherin,
downregulated vimentin, and ultimately decreased epithelial
to mesenchymal transition (Huang et al., 2015). The role of
reactive oxidative species in HIPK2 expression was further
confirmed when treatment with n-acetylcysteine, a reactive
oxidative species scavenger, attenuated the HIV-induced increase
in caspase 3 activity and epithelial-mesenchymal transition
marker expression in RTECs in vitro (Jin et al., 2012) and resulted
in increased SIAH1 expression and reduced HIPK2 expression
in Tg26 mice, ultimately resulting in a partial reduction in
proteinuria, and attenuation of azotemia and kidney fibrosis.
Pros and Cons of HIPK2 as Potential
Anti-Fibrosis Target
The above data suggest that inhibition of HIPK2 would mitigate
renal fibrosis progression in kidney disease. Importantly, genetic
ablation of HIPK2 does not result in a significant phenotype,
as opposed to the detrimental effects seen with partial NF-κB
inhibition, making HIPK2 an attractive target for therapy (Doi
et al., 1997). Although recent studies suggest that it is possible to
develop specific HIPK2 inhibitors (Cozza et al., 2014), at present,
there are no specific HIPK2 inhibitors available for clinical
testing. Development of specific HIPK2 inhibitors is necessary,
since unlike the HIPK2 KO mice that show no overt phenotype,
HIPK1 and HIPK2 double KO mice are lethal.
One concern of using HIPK2 inhibitors as anti-fibrosis
therapy is its tumor suppressive effects. HIPK2 suppresses tumor
growth by activating p53 and inducing tumor cell apoptosis (Li
et al., 2007; Wei et al., 2007; Stanga et al., 2010; D’Orazi et al.,
2012; Mao et al., 2012). In addition to having tumor-suppressive
effects, HIPK2 is also needed for TGF-β-mediated survival of
midbrain dopaminergic neurons (Zhang et al., 2007; Lanni et al.,
2010; Stanga et al., 2010; Chalazonitis et al., 2011). The potential
tumor suppressive and neurologic effects of HIPK2 suggest
that inhibitors of HIPK2 could have potential adverse effects
which need to be carefully watched for in future clinical studies.
However, it is likely that the effects of HIPK2 are quite different
between tumor cells and non-tumor cells and HIPK2 inhibitors
could be used in CKD patients without history of cancers using
the same criteria that we currently use for immunosuppressive
medication in patients with kidney disease.
Conclusion
Several key signaling pathways that mediate renal fibrosis
have been identified. This has been shown both in vitro
in cultured kidney cells and in vivo in animal models
of kidney disease. However, currently, none of the drugs
targeting these pathways have been proven to be effective
anti-fibrosis therapy for kidney disease in large clinical trials.
One potential reason is that renal fibrosis is mediated by
a complex signaling network of several different pathways.
Therefore, targeting one pathway is not enough to be effective.
HIPK2 has been identified as a master regulator of kidney
fibrosis and acts upstream of several major fibrosis-signaling
pathways. Controlling HIPK2’s activities might be an effective
approach to reduce the progression of kidney fibrosis. However,
it is important to note that HIPK2 also has some onco-
suppressor functions and that loss of HIPK2 may also lead
to neurodegenerative disease (Lanni et al., 2010). Therefore,
we need to carefully monitor for potential side effects during
future clinical studies. Further structural and functional studies
of HIPK2 may aid in the development of more specific HIPK2
inhibitors as anti-fibrosis therapy without causing these side
effects.
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